In this special issue, we have compiled an up-to-date review articles on the topic of targeting MET in human cancer therapy, reexamining the critical issues of MET biology, genomic alterations, predictive biomarkers, assay development, therapeutic drug development and clinical trial studies design issues and data update. While most of scientific discoveries might have come to light as serendipity of discovery, many more were accomplished out of patience, perseverance and methodical scientific quest. It is clear that there remains many challenges in the clinical therapeutics development against MET as actionable cancer therapy target despite intensive preclinical and clinical investigations in the past. Nonetheless, it is perhaps not unreasonable to anticipate clinically relevant breakthrough in the insights and optimal treatment strategies that would arrive in the next few years as a result of the clinical adoption of new generation genomic sequencing and molecular profiling technologies, coupled with new waves of MET targeting clinical studies, both with newer agents and newer study designs.Preface on MET as Actionable Target in Cancer Therapy
Review Article on MET as Actionable Target in Cancer Therapy
Sara Pilotto, Anastasios Gkountakos, Luisa Carbognin, Aldo Scarpa, Giampaolo Tortora, Emilio Bria
Apurva K. Srivastava, Tony Navas, William G. Herrick, Melinda G. Hollingshead, Donald P. Bottaro, James H. Doroshow, Ralph E. Parchment
Brian Ko, Tianfang He, Shirish Gadgeel, Balazs Halmos
Hye-Min Jeon, Jeongwu Lee
Disclosure:
The series “MET as Actionable Target in Cancer Therapy” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Patrick C. Ma served as the unpaid Guest Editor for the series.
